Spinogenix has received clearance from the U.S. Food and Drug Administration (FDA) to launch an expanded access program (EAP) for SPG302, its oral treatment for amyotrophic lateral sclerosis (ALS). EAPs, also known as compassionate use programs, allow people with serious or life-threatening conditions to access experimental therapies outside of…

Fire the flare guns, turn on the ship-to-shore radio, and holler “Mayday! Mayday! Mayday!” That’s the first order of business for a ship that’s sinking. It needs attention — lots of attention. There’s even an official mayday relay procedure, which lets ships in the vicinity take turns relaying the distress…

The real-world use of Radicava (edaravone), an infusion treatment approved for amyotrophic lateral sclerosis (ALS), may cause serious side effects — such as liver problems, blood clots, pain, brain bleeding, and infection — not previously listed in its label, according to data from the U.S. drug regulatory agency’s…

Prilenia Therapeutics has entered a collaboration and license agreement with Ferrer to codevelop and commercialize pridopidine, its therapy candidate for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), in Europe and other select markets. The partnership comes as pridopidine nears an expected regulatory decision in the European Union, where…

ALS groups are asking lawmakers to preserve federal funding for the National ALS Registry and National ALS Biorepository, the first and only comprehensive nationwide resource to collect and analyze data for better understanding amyotrophic lateral sclerosis (ALS). “A recently leaked draft memo from the U.S. Department of Health and…